ERBB2 and cancer: The HFA-ICOS cardiotoxicity risk score encapsulates baseline risk stratification before the receipt of the following cancer treatment: Anthracycline-based chemotherapy, Human epidermal growth factor receptor-2 (HER-2) targeted therapy, Vascular endothelial growth factor inhibitors, Targeted kinase inhibitors, Proteasome inhibitors, Immunomodulatory drugs, Rapidly accelerated fibrosarcoma (RAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors, and androgen-deprivation therapy.